Literature DB >> 17981790

Blocking of IL-6 signaling pathway prevents CD4+ T cell-mediated colitis in a T(h)17-independent manner.

Daisuke Noguchi1, Daiko Wakita, Masaki Tajima, Shigeru Ashino, Yoichiro Iwakura, Yue Zhang, Kenji Chamoto, Hidemitsu Kitamura, Takashi Nishimura.   

Abstract

Naive CD4(+) T cells rapidly proliferate to generate effector cells after encountering an antigen and small numbers survive as memory T cells in preparation for future immunological events. In the present work, adoptive transfer of naive CD4(+) T cells into RAG2(-/-) mice caused the generation of memory-type effector T cells including T(h)1, T(h)2, T(h)17 and regulatory T cells, and eventually induced T cell-dependent colitis. We found here that blocking of the IL-6R with a specific mAb remarkably inhibited the CD4(+) T cell-mediated colitis in parallel with the inhibition of T(h)17 cell generation. However, the transfer of naive CD4(+) T cells prepared from IL-17(-/-) mice still induced severe colitis. At the effector phase, the mAb significantly inhibited IL-17 but not IFN-gamma production. The blockade of IL-6 signaling enhanced the generation of IL-4- and IL-10-producing CD4(+) T cells, and inhibited up-regulation of tumor necrosis factor -alpha mRNA expression in the colon. These findings clearly demonstrated that IL-6 is a critical factor for the induction of colitis by expansion of naive CD4(+) T cells in RAG2(-/-) mice. Thus, the IL-6-mediated signaling pathway may be a significant therapeutic target in T cell-mediated autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17981790     DOI: 10.1093/intimm/dxm114

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  26 in total

Review 1.  Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity.

Authors:  Peter J Morrison; Sarah J Ballantyne; Marika C Kullberg
Journal:  Immunology       Date:  2011-06-02       Impact factor: 7.397

Review 2.  Animal models of IBD: linkage to human disease.

Authors:  Atsushi Mizoguchi; Emiko Mizoguchi
Journal:  Curr Opin Pharmacol       Date:  2010-06-08       Impact factor: 5.547

3.  Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis.

Authors:  Stacey N Harbour; Craig L Maynard; Carlene L Zindl; Trenton R Schoeb; Casey T Weaver
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-18       Impact factor: 11.205

Review 4.  Stat3: friend or foe in colitis and colitis-associated cancer?

Authors:  Jie Han; Arianne L Theiss
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

5.  A Small Molecule Inhibitor of ITK and RLK Impairs Th1 Differentiation and Prevents Colitis Disease Progression.

Authors:  Hyoung-Soo Cho; Hyun Mu Shin; Helena Haberstock-Debic; Yan Xing; Timothy D Owens; Jens Oliver Funk; Ronald J Hill; J Michael Bradshaw; Leslie J Berg
Journal:  J Immunol       Date:  2015-10-14       Impact factor: 5.422

6.  Development of a T(H)17 immune response during the induction of murine syngeneic graft-versus-host disease.

Authors:  J Anthony Brandon; C Darrell Jennings; Alan M Kaplan; J Scott Bryson
Journal:  Cytokine       Date:  2010-09-15       Impact factor: 3.861

Review 7.  IL-17F: regulation, signaling and function in inflammation.

Authors:  Seon Hee Chang; Chen Dong
Journal:  Cytokine       Date:  2009-02-23       Impact factor: 3.861

8.  Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease.

Authors:  Rupali Das; Xiao Chen; Richard Komorowski; Martin J Hessner; William R Drobyski
Journal:  Blood       Date:  2008-12-04       Impact factor: 22.113

Review 9.  Balance of Th1 and Th17 effector and peripheral regulatory T cells.

Authors:  Jens Lohr; Birgit Knoechel; David Caretto; Abul K Abbas
Journal:  Microbes Infect       Date:  2009-04-17       Impact factor: 2.700

Review 10.  Interleukin-23 and Th17 cells in the control of gut inflammation.

Authors:  Ivan Monteleone; Francesco Pallone; Giovanni Monteleone
Journal:  Mediators Inflamm       Date:  2009-05-27       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.